Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. / Meier, S; Hücking, K; Ritzel, R; Holst, Jens Juul; Schmiegel, W H; Nauck, M A.

I: Hormone and Metabolic Research. Supplement, Bind 35, Nr. 9, 09.2003, s. 551-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Meier, S, Hücking, K, Ritzel, R, Holst, JJ, Schmiegel, WH & Nauck, MA 2003, 'Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers', Hormone and Metabolic Research. Supplement, bind 35, nr. 9, s. 551-6. https://doi.org/10.1055/s-2003-42658

APA

Meier, S., Hücking, K., Ritzel, R., Holst, J. J., Schmiegel, W. H., & Nauck, M. A. (2003). Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Hormone and Metabolic Research. Supplement, 35(9), 551-6. https://doi.org/10.1055/s-2003-42658

Vancouver

Meier S, Hücking K, Ritzel R, Holst JJ, Schmiegel WH, Nauck MA. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Hormone and Metabolic Research. Supplement. 2003 sep.;35(9):551-6. https://doi.org/10.1055/s-2003-42658

Author

Meier, S ; Hücking, K ; Ritzel, R ; Holst, Jens Juul ; Schmiegel, W H ; Nauck, M A. / Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. I: Hormone and Metabolic Research. Supplement. 2003 ; Bind 35, Nr. 9. s. 551-6.

Bibtex

@article{b86f88cfb5db41b09e0f7f7f901f2fe2,
title = "Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers",
abstract = "BACKGROUND/AIMS: The term memory effect refers to the phenomenon that B cell stimuli retain some of their insulinotropic effects after they have been removed. Memory effects exist for glucose and sulfonylureas. It is not known whether there is a B-cell memory for incretin hormones such as GLP-1.SUBJECTS/METHODS: Eight healthy young volunteers were studied on four occasions in the fasting state. In one experiment, placebo was administered (a). in three more experiments (random order), synthetic GLP-1 (7 - 36 amide) at 1.2 pmol/kg/min was administered over a period of three hours. At 0 min, a bolus of glucose was injected intravenously (0.33 g/kg body weight). GLP-1 was infused from (b). - 60 to 120 min, (c). - 210 to - 30 min, or (d). - 300 to - 120 min. Glucose (glucose oxidase), insulin, C-peptide, GLP-1, and glucagon (immunoassays) were determined. Statistical analysis was carried out by ANOVA and appropriate post hoc tests.RESULTS: GLP-1 plasma levels during the infusion periods were elevated to 89 +/- 9, 85 +/- 13, and 89 +/- 6 pmol/l (p < 0.0001 vs. placebo, 10 +/- 1 pmol/l). Glucose was eliminated faster (p < 0.0001), with an enhanced negative rebound (p = 0.014), and insulin and C-peptide increments were greater after intravenous glucose administration (p < 0.0001) if GLP-1 was administered during the injection of the glucose bolus, but not if GLP-1 had been administered until 120 or 30 min before the glucose load. There was a trend towards higher insulin concentrations (p = 0.056) five minutes after glucose with GLP-1 administered until - 30 min before the glucose load. Glucagon was suppressed by exogenous glucose, but increased significantly (p = 0.013) during the induction of reactive hypoglycemia after glucose injection during GLP-1 administration.CONCLUSION: 1). No memory effect appears to exist for insulinotropic actions of GLP-1, in line with clinical data. 2). Reactive hypoglycemia causes a prompt rise in glucagon despite pharmacological circulating concentrations of GLP-1. 3). Similar studies should be performed in Type 2-diabetic patients, because exposure to GLP-1 might recruit dormant pancreatic B cells to become glucose-competent, and this might contribute to the overall antidiabetogenic effect of GLP-1 in such patients.",
keywords = "Adult, Analysis of Variance, Blood Glucose, C-Peptide, Fasting, Glucagon, Glucagon-Like Peptide 1, Humans, Insulin, Islets of Langerhans, Male, Peptides, Reference Values",
author = "S Meier and K H{\"u}cking and R Ritzel and Holst, {Jens Juul} and Schmiegel, {W H} and Nauck, {M A}",
year = "2003",
month = sep,
doi = "10.1055/s-2003-42658",
language = "English",
volume = "35",
pages = "551--6",
journal = "Hormone and Metabolic Research. Supplement",
issn = "0170-5903",
publisher = "GeorgThieme Verlag",
number = "9",

}

RIS

TY - JOUR

T1 - Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers

AU - Meier, S

AU - Hücking, K

AU - Ritzel, R

AU - Holst, Jens Juul

AU - Schmiegel, W H

AU - Nauck, M A

PY - 2003/9

Y1 - 2003/9

N2 - BACKGROUND/AIMS: The term memory effect refers to the phenomenon that B cell stimuli retain some of their insulinotropic effects after they have been removed. Memory effects exist for glucose and sulfonylureas. It is not known whether there is a B-cell memory for incretin hormones such as GLP-1.SUBJECTS/METHODS: Eight healthy young volunteers were studied on four occasions in the fasting state. In one experiment, placebo was administered (a). in three more experiments (random order), synthetic GLP-1 (7 - 36 amide) at 1.2 pmol/kg/min was administered over a period of three hours. At 0 min, a bolus of glucose was injected intravenously (0.33 g/kg body weight). GLP-1 was infused from (b). - 60 to 120 min, (c). - 210 to - 30 min, or (d). - 300 to - 120 min. Glucose (glucose oxidase), insulin, C-peptide, GLP-1, and glucagon (immunoassays) were determined. Statistical analysis was carried out by ANOVA and appropriate post hoc tests.RESULTS: GLP-1 plasma levels during the infusion periods were elevated to 89 +/- 9, 85 +/- 13, and 89 +/- 6 pmol/l (p < 0.0001 vs. placebo, 10 +/- 1 pmol/l). Glucose was eliminated faster (p < 0.0001), with an enhanced negative rebound (p = 0.014), and insulin and C-peptide increments were greater after intravenous glucose administration (p < 0.0001) if GLP-1 was administered during the injection of the glucose bolus, but not if GLP-1 had been administered until 120 or 30 min before the glucose load. There was a trend towards higher insulin concentrations (p = 0.056) five minutes after glucose with GLP-1 administered until - 30 min before the glucose load. Glucagon was suppressed by exogenous glucose, but increased significantly (p = 0.013) during the induction of reactive hypoglycemia after glucose injection during GLP-1 administration.CONCLUSION: 1). No memory effect appears to exist for insulinotropic actions of GLP-1, in line with clinical data. 2). Reactive hypoglycemia causes a prompt rise in glucagon despite pharmacological circulating concentrations of GLP-1. 3). Similar studies should be performed in Type 2-diabetic patients, because exposure to GLP-1 might recruit dormant pancreatic B cells to become glucose-competent, and this might contribute to the overall antidiabetogenic effect of GLP-1 in such patients.

AB - BACKGROUND/AIMS: The term memory effect refers to the phenomenon that B cell stimuli retain some of their insulinotropic effects after they have been removed. Memory effects exist for glucose and sulfonylureas. It is not known whether there is a B-cell memory for incretin hormones such as GLP-1.SUBJECTS/METHODS: Eight healthy young volunteers were studied on four occasions in the fasting state. In one experiment, placebo was administered (a). in three more experiments (random order), synthetic GLP-1 (7 - 36 amide) at 1.2 pmol/kg/min was administered over a period of three hours. At 0 min, a bolus of glucose was injected intravenously (0.33 g/kg body weight). GLP-1 was infused from (b). - 60 to 120 min, (c). - 210 to - 30 min, or (d). - 300 to - 120 min. Glucose (glucose oxidase), insulin, C-peptide, GLP-1, and glucagon (immunoassays) were determined. Statistical analysis was carried out by ANOVA and appropriate post hoc tests.RESULTS: GLP-1 plasma levels during the infusion periods were elevated to 89 +/- 9, 85 +/- 13, and 89 +/- 6 pmol/l (p < 0.0001 vs. placebo, 10 +/- 1 pmol/l). Glucose was eliminated faster (p < 0.0001), with an enhanced negative rebound (p = 0.014), and insulin and C-peptide increments were greater after intravenous glucose administration (p < 0.0001) if GLP-1 was administered during the injection of the glucose bolus, but not if GLP-1 had been administered until 120 or 30 min before the glucose load. There was a trend towards higher insulin concentrations (p = 0.056) five minutes after glucose with GLP-1 administered until - 30 min before the glucose load. Glucagon was suppressed by exogenous glucose, but increased significantly (p = 0.013) during the induction of reactive hypoglycemia after glucose injection during GLP-1 administration.CONCLUSION: 1). No memory effect appears to exist for insulinotropic actions of GLP-1, in line with clinical data. 2). Reactive hypoglycemia causes a prompt rise in glucagon despite pharmacological circulating concentrations of GLP-1. 3). Similar studies should be performed in Type 2-diabetic patients, because exposure to GLP-1 might recruit dormant pancreatic B cells to become glucose-competent, and this might contribute to the overall antidiabetogenic effect of GLP-1 in such patients.

KW - Adult

KW - Analysis of Variance

KW - Blood Glucose

KW - C-Peptide

KW - Fasting

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Insulin

KW - Islets of Langerhans

KW - Male

KW - Peptides

KW - Reference Values

U2 - 10.1055/s-2003-42658

DO - 10.1055/s-2003-42658

M3 - Journal article

C2 - 14517773

VL - 35

SP - 551

EP - 556

JO - Hormone and Metabolic Research. Supplement

JF - Hormone and Metabolic Research. Supplement

SN - 0170-5903

IS - 9

ER -

ID: 132055857